Harden TK, Lazarowski ER. The UDP-sugar-sensing P2Y 14 receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils. The G i-coupled P2Y 14 receptor (P2Y14-R) is potently activated by UDP-sugars and UDP. Although P2Y 14-R mRNA is prominently expressed in circulating neutrophils, the signaling pathways and functional responses associated with this receptor are undefined. In this study, we illustrate that incubation of isolated human neutrophils with UDPglucose resulted in cytoskeleton rearrangement, change of cell shape, and enhanced cell migration. We also demonstrate that UDP-glucose promotes rapid, robust, and concentration-dependent activation of RhoA in these cells. Ecto-nucleotidases expressed on neutrophils rapidly hydrolyzed extracellular ATP, but incubation with UDPglucose for up to 1 h resulted in negligible metabolism of the nucleotide-sugar. HL60 human promyelocytic leukemia cells do not express the P2Y 14-R, but neutrophil differentiation of HL60 cells with DMSO resulted in markedly enhanced P2Y 14-R expression. Accordingly, UDP-glucose, UDP-galactose, and UDP-N-acetylglucosamine promoted Rho activation in differentiated but not in undifferentiated HL60 cells. Stable expression of recombinant human P2Y 14-R conferred UDP-sugar-promoted responses to undifferentiated HL60 cells. UDP-glucose-promoted RhoA activation also was accompanied by enhanced cell migration in differentiated HL60 cells, and these responses were blocked by Rho kinase inhibitors. These results support the notion that UDP-glucose is a stable and potent proinflammatory mediator that promotes P2Y 14-R-mediated neutrophil motility via Rho/Rho kinase activation.
purinergic receptors THE P2Y14 RECEPTOR (P2Y 14 -R) was identified as a G i -coupled receptor that is potently and selectively activated by UDPglucose, UDP-galactose, UDP-glucuronic acid, and UDP-Nacetylglucosamine (6) . UDP also potently activates the P2Y 14 -R (5), but UTP, ATP, ADP, and other naturally occurring di-or triphosphate nucleotides are not agonists at this receptor (5, 6) . P2Y 14 -R mRNA is expressed throughout the brain (6) and was markedly upregulated after immunological challenge with lipopolysaccharide (37) . P2Y 14 -R also is expressed at the mRNA level in several peripheral tissues, including immune-competent cells (21) . Relatively high P2Y 14 -R levels were observed in immature human dendritic cells that mature and migrate to sites of inflammation (47) , in bone marrow hematopoietic cells, where it was proposed to mediate chemotaxis (33) , and in RBL-2H3 mast cells, where UDP-glucose promoted Ca 2ϩ mobilization, phosphorylation of ERK1/2, and ␤-hexosaminidase release (18) .
The high level of expression of P2Y 14 -R in leucocytes and other immune cells supports a potential role for this receptor in immune system homeostasis, but association of UDP-glucose effects with P2Y 14 -R activity has been difficult to establish in these tissues. Of particular relevance to inflammation, circulating polymorphonuclear neutrophils (PMNs) are the peripheral human cell type that most abundantly expresses P2Y 14 -R mRNA (37) , but the functional consequences of P2Y 14 -R activation in PMNs remain undefined. Scrivens and Dickenson (43) reported that UDP-glucose promoted a modest inhibition of forskolin-stimulated cyclic AMP formation in neutrophils, but other UDP-sugars known to promote P2Y 14 -R activation had no effect (43) . UDP-glucose also evoked a modest increase in ERK phosphorylation in these cells, but this response was observed only at high micromolar/submillimolar concentrations and was not mimicked by other UDP-sugars (43) . UDPglucose failed to induce elastase secretion from human PMNs (43) . Thus, unambiguous association of the expression of P2Y 14 -R transcripts with P2Y 14 -R-mediated responses in PMNs remains to be established.
In the present study, we used isolated human neutrophils and neutrophil-like HL60 human promyelocytic leukemia cells to illustrate that UDP-glucose evokes activation of Rho GTPases in a P2Y 14 -R expression-dependent manner. Rho activation was accompanied by cytoskeleton remodeling and enhanced cell motility. 1 
MATERIALS AND METHODS
Human neutrophils and cell cultures. Peripheral neutrophils were isolated from fresh venous blood samples from healthy volunteers with written informed consent and the approval of the University of North Carolina Institutional Review Board (IRB). Neutrophils were isolated (Ͼ98% purity) using Ficoll-paque Plus (GE Healthcare) and 3% dextran as described previously (29, 52) . HL60 cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum at a cell density of 3 ϫ 10 5 cells/ml, as previously described (16) . Neutrophil differentiation of HL60 (dHL60) cells was achieved by inclusion of 1.3% DMSO in the culture medium for 5 days (16) . Neutrophils and HL60 cells were rinsed and, except when indicated otherwise, cells were incubated (1-10 ϫ 10 6 cells/ml) in HEPESbuffered (pH 7.4) Hanks' balanced salt solution supplemented with 1.6 mM CaCl2 and 0.8 mM MgCl2 (HBSS). Apyrase (1 U/ml) was added to PMN suspensions during the isolation steps. Inclusion of apyrase ensures the removal of ATP and UTP potentially released from damaged or mechanically activated neutrophils, e.g., during cell washes and centrifugations (28) , and thus, avoids unwanted activation of P2Y 2 or P2X1 receptors expressed in these cells (32, 51, 52) . HPLC analysis verified that 100 M ATP and 100 M UTP were completely hydrolyzed by 1 U/ml apyrase in Ͻ5 min, while 100 M UDPglucose remained essentially unchanged after 90 min (not shown).
Extracellular metabolism of UDP-glucose and ATP. Neutrophils (2 ϫ 10 6 /ml) were incubated in HBSS (supplemented as above) in the presence of 100 M UDP-glucose or 100 M ATP, or in the presence of 0.1 Ci UDP-[ 3 H]glucose (26 Ci/mmol) or 0.1 Ci [ 3 H]ATP (37 Ci/mmol). At the times indicated, cells were centrifuged and nucleotides present in the supernatant were separated by HPLC (Waters) via a Nova-Pack C18 column. Absorbance at ϭ 260 nm and radioactivity were quantified on-line as previously described (27, 31) .
Stable expression of P2Y 14-R in HL60 cells. Retroviruses encoding the human P2Y14-R were produced using the pLXSN expression vector, as previously described (16) . HL60 cells were infected with P2Y14-R-bearing retroviruses and selected in medium containing 0.5 mg/ml G418.
RhoA pull-down assays. GTP-bound RhoA was measured using the Rho Activation Assay Biochem Kit, following the manufacturer's instructions. Briefly, neutrophils or 12-h serum-starved HL60 cells were rinsed and suspended in HBSS (10 7 cells/ml), preincubated for 45 min at 37°C, and incubated for 1 min (or the indicated times) with vehicle or agonists. Incubations were terminated by addition of lysis buffer (supplied in the kit) followed by rapid centrifugation, and aliquots of supernatants were incubated with Rhotekin-RBD beads for 1 h at 4°C. RhoGTP from pull-down assays and total RhoA were resolved by SDS-PAGE and analyzed by Western blotting, as previously described (45) . Apyrase (1 U/ml) was added to the neutrophil suspension during these incubations.
Chemotaxis. Cells were loaded with 2.5 M carbocyanide dye DID (Vybrant Cell-Labeling Solutions, Molecular Probes) for 15 min (10 6 cells/ml) in RPMI medium (PMN) or HBSS (HL60 cells) supplemented with 10% heat-inactivated fetal bovine serum, rinsed twice, and suspended in RPMI or HBSS, as above. Chemotaxis was quantified in 96-multiwell FluoroBlock insert (BD Falcon), following the manufacturer's instructions. Briefly, vehicle or agonist was added to the lower compartment (225 l), and 75-l of a cell suspension (2 ϫ 10 5 cells) was loaded onto the upper compartment, separated from the bottom by a 3-m pore diameter polyethylene terephthalate (PEI) filter membrane (specially designed to block light transmission, simplifying detection of migrating fluorescently labeled cells). Agonists were added to both the lower and the upper compartments in experiments designed to assess random migration. The fluorescent signal (F, 612 nm excitation/670 nm emission) was read at the indicated times, using a Tecan Infinite M1000 plate reader. The chemotaxis index (Ctx Index) was defined as:
where F1 and F0 represent the fluorescence signal from stimulated and nonstimulated cells, respectively, and FB is background fluorescence measured in the absence of cells.
To measure the rate of diffusion of UDP-glucose through the filter membrane, 100 M UDP-[ 3 H]glucose (200,000 counts per minute) was added to the lower compartment, and the radioactivity present in both the lower and the upper compartments was quantified at various times by liquid scintillation counting. UDP-glucose diffusion was calculated as the percentage of counts present at a given time (T) in the upper compartment, relative to T ϭ ϱ (i.e., at equilibrium).
Staining of F-actin and confocal microscopy. Neutrophils (2 ϫ 10 6 ) were incubated with agonist or vehicle for 15 min, fixed with 4% paraformaldehyde (5 min), rapidly centrifuged, and resuspended in 0.1% Triton X-100 for 20 min. Cells were stained with Alex-aFluor488-phalloidin to label F-actin and propidium iodide to label the nuclei. Cells were cytospun and mounted on coverslips and viewed in a Leica SP5 confocal microscope, as previously described (24) .
Reagents. UDP-glucose was purchased from Fluka (Sigma-Aldrich, St. Louis, MO). HPLC analysis of stock solutions of UDPglucose indicated no detectable contamination with ATP or any other nucleotide signaling molecule (not shown). Apyrase and nucleotide pyrophosphatase from Crotalus adamanteus were also from Sigma. The RhoA activation Assay Biochem kits (including anti-RhoA antibody) were purchased from Cytoskeleton (Denver, CO). H1152, Y27632, and wortmannin were obtained from Calbiochem (La Jolla, CA). UDP-[ 3 H]glucose and [ 3 H]ATP were purchased from Amersham Pharmacia Biotech (Piscataway, NJ). All other chemicals were of the highest purity available.
Data analysis. Statistical analysis was performed using ANOVA with post hoc Tukey honestly significant difference (HSD); P Յ 0.05 (JMP Genomics, version 4.1, SAS, Cary, NC).
RESULTS

Stability of UDP-glucose on human neutrophils.
The capacity of human neutrophils to rapidly hydrolyze extracellular ATP and other nucleotides is well established (11, 25, 42) , but the extent to which these cells metabolize UDP-glucose is not known. Thus, we quantified the stability of this nucleotidesugar in neutrophil suspensions using HPLC analysis. Incubation of neutrophils with 100 M UDP-glucose for 60 min resulted in negligible metabolism of the nucleotide-sugar ( Fig. 1A) , i.e., Ͻ1% of the initial UDP-glucose was recovered as UMP. In contrast, neutrophils rapidly hydrolyzed 100 M ATP, displaying an apparent hydrolysis rate of V hyd ϭ 7.3 nmol/min ϫ 10 6 cells ( Fig. 1A ). ADP and AMP were the major products of ATP metabolism (not shown). Stability of nucleotides in the presence of PMNs also was monitored using UDP-[ 3 H]glucose or [ 3 H]ATP as high specific activity radiotracers. As shown in Fig. 1B , [ 3 H]ATP decayed with an apparent half-life of 2.5 min, while UDP-[ 3 H]glucose remained essentially unchanged after 60 min. These results are in agreement with previous reports indicating that NTPDase1, which hydrolyzes ATP and other NTPs and NDPs, but not UDP-sugars, is expressed on the surface of human neutrophils (11, 25, 42) . The data also indicate that little or no ecto-nucleotide pyrophosphatase activity (which hydrolyzes UDP-sugars) is present on these cells.
UDP-glucose promotes actin cytoskeleton reorganization, cell migration, and Rho activation in human neutrophils. We tested the hypothesis that UDP-glucose acts as an extracellular signaling molecule for neutrophils by first assessing its effect on cell shape and actin cytoskeleton reorganization, visualized via differential interference contrast (DIC) and fluorescence microscopy. In the absence of external stimulus, most neutrophils displayed round shape and phalloidin uniformly stained the cortical actin fibers (Fig. 2, A and B, left) . Incubation of neutrophils for 15 min with 100 M UDP-glucose resulted in changes in cell shape (i.e., from round to elongated shape) that were accompanied by a sharp increase in the intensity of the cortical actin staining and the formation of a broad ruffle-like structure in one cellular pole (Fig. 2, A and B, right) . These morphological changes were observed in 56.0 Ϯ 4% of the cells incubated with UDP-glucose, as opposed to 15.2 Ϯ 3% in untreated cells (means Ϯ SE). The data suggest that UDPglucose promotes changes in the organization of actin fibers in neutrophils.
Observation of UDP-glucose-dependent cell shape change and cytoskeleton rearrangement suggests that this nucleotidesugar acts as an extracellular signaling molecule to regulate cellular functions associated with neutrophil motility. Studies using a modified Boyden chamber illustrated that UDP-glucose promotes PMN migration ( Fig. 3 ). That is, enhanced cell migration was observed when UDP-glucose was added to the lower compartment of the chemotaxis chamber, but not when the concentration gradient of agonist was abolished by addition of UDP-glucose to both compartments (Fig. 3A) . Thus, UDPglucose enhances neutrophil chemotaxis but has no effect on random migration as illustrated by its lack of effect in the absence of a concentration gradient. In agreement with our HPLC analysis indicating that UDP-glucose stock solutions contained no detectable ATP or UTP (not shown), chemotaxis was not affected by inclusion of apyrase in the lower compartment of the chamber (Fig. 3B ). However, UDP-glucose-evoked chemotaxis was partially reduced when apyrase was added to both lower and upper compartments, suggesting that ATP/UTP released from neutrophils contributed, at least in part, to this response.
Chemotaxis was observed in response to the addition of 1 M UDP-glucose and was maximal with 30 M UDPglucose ( Fig. 3C ). These nominal concentration values overestimate the actual concentration of agonist reaching the cells, since only ϳ20% of the UDP-glucose added to the lower compartment was recovered in the upper compartment after 60 min ( Fig. 3C, inset) . Based on the concentration of agonist estimated to reach the upper chamber at the time of the chemotaxis measurement, UDP-glucose promoted neutrophil chemotaxis with potency (EC 50 ϭ 0.7 M; Fig. 3C ) similar to that observed for activation of the P2Y 14 -R in a variety of test systems (21) .
Members of the Rho family of GTPases play critical roles in the cytoskeletal remodeling response associated with neutrophil motility (39, 40) . Rho-associated kinase also is important for motile function of neutrophils (39) , and UDP-glucosepromoted PMN migration was completely inhibited by the Rho kinase inhibitor H1152 (1 M) ( Fig. 3A) .
We used the Rhotekin-RBD pull-down assay to examine the extent to which UDP-glucose promotes activation of RhoA in PMNs. Addition of UDP-glucose to isolated neutrophils resulted in rapid (1 min) formation of RhoA-GTP, which was evident with 100 nM UDP-glucose and was maximal with 10 M UDP-glucose (EC 50 ϭ 0.9 M; Fig. 3D ), consistent with UDP-glucose acting through the P2Y 14 -R (21) .
Collectively, the data in Figs. 1-3 indicate that UDP-glucose is a potent and highly stable agonist of the P2Y 14 -R endogenously expressed by human neutrophils. Activation of this G protein-coupled receptor promotes RhoA activation, cell shape changes, and chemotaxis in these cells.
UDP-glucose promotes P2Y 14 -R-mediated activation of RhoA in HL60 cells. To assess more extensively the involvement of P2Y 14 -R in UDP-glucose-evoked RhoA activation in neutrophils, studies were conducted using neutrophil-like HL60 human promyelocytic leukemia cells. We previously reported that undifferentiated HL60 cells do not express P2Y 14 -R transcripts (5, 16) , and as is illustrated in Fig. 4A , these cells also did not respond to UDP-glucose with an increase in RhoA-GTP formation. UDP-galactose and UDP-Nacetylglucosamine also had no effect on RhoA activation (not shown), but robust formation of RhoA-GTP occurred in the presence of ATP (Fig. 4A) , likely reflecting activation of endogenous P2X1 and/or P2Y 2 receptors (4, 5, 10, 52).
Differentiation of HL60 cells with DMSO (dHL60 cells) results in P2Y 14 -R mRNA expression (5, 16) , and as is illustrated in Fig. 4B , RhoA activation in dHL60 cells was observed with low micromolar concentrations of UDP-glucose (EC 50 ϭ 0.7 M), consistent with the concentration dependence of a P2Y 14 -R. To support the conclusion that activation of RhoA occurs through an extracellular signaling action of UDP-glucose, the effects of Crotalus adamanteus nucleotide pyrophosphatase, a phosphodiesterase (PDE) that hydrolyzes nucleotide-sugars and nucleotides (31) , and apyrase, which hydrolyzes nucleotides but not nucleotide-sugars (31), were examined. Activation of RhoA in the presence of UDP-glucose was virtually eliminated by preincubation of UDP-glucose with 1 U/ml PDE (Fig. 4C ), but not by 1 U/ml apyrase (Fig. 4D ). UDP-galactose and UDP-N-acetylglucosamine also promoted RhoA activation in dHL60 cells (Fig. 4E ).
To further assess the involvement of the P2Y 14 -R in UDPglucose-evoked RhoA activation in HL60 cells, the human P2Y 14 -R was stably expressed in these cells (P2Y 14 -HL60 cells) via retroviral infection (16) . In contrast to the lack of effect observed in undifferentiated HL60 cells (see Fig. 4A ), UDP-glucose promoted RhoA activation in undifferentiated P2Y 14 -HL60 cells (Fig. 5 ). UDP-glucose-evoked RhoA activation was robust between 1 and 15 min following agonist addition, and it faded after 30 min (Fig. 5A ). UDP-glucosepromoted RhoA activation in P2Y 14 -HL60 cells exhibited an EC 50 value of 0.4 M (Fig. 5B ). UDP-galactose and UDP-Nacetylglucosamine also promoted RhoA-GTP formation in undifferentiated P2Y 14 -HL60 cells (Fig. 5C) .
Pertussis toxin and phosphoinositide 3-kinase inhibition abolish P2Y 14 -R-promoted Rho activation in HL60 cells. Several studies from our and other groups support the notion that the human P2Y 14 -R signals through G i (6, (15) (16) (17) 31) . In agreement with this concept, preincubation of dHL60 ( Fig. 6A ) with pertussis toxin abolished UDP-glucose-promoted RhoA (44) . Consistent with this hypothesis, incubation of dHL60 cells with wortmannin, a selective inhibitor of PI-3-kinase, abolished UDP-glucose-promoted RhoA activation (Fig. 6B) .
UDP-glucose promotes dHL60 cell migration. Incubation of dHL60 cells with 100 M UDP-glucose (added to the lower compartment of the Boyden chamber) resulted in enhanced cell migration. As shown above with neutrophils, cell migration was not observed when the concentration gradient of agonist was abolished by addition of UDP-glucose to both compartments of the chamber, and it was inhibited by the Rho kinase inhibitors H1152 and Y27632 (Fig. 7A ). As predicted, UDPglucose-evoked dHL60 cell migration was abolished by preincubation of UDP-glucose with nucleotide pyrophosphatase, but not by apyrase (Fig. 7A ). Addition of apyrase to the lower compartment of the chamber had no effect on dHL60 cell chemotaxis, but UDP-glucose-evoked chemotaxis was partially reduced when apyrase was also present in the upper chamber (Fig. 7B) . The concentration-effect relationship for UDP-glucose-promoted chemotaxis in dHL60 is illustrated in Fig. 7C . Based on the diffusion rate of agonist through the chemotaxis membrane (see Fig. 3C ), the estimated EC 50 value for UDP-glucose-promoted dHL60 cell chemotaxis was 0.5 M (Fig. 7C ). 
DISCUSSION
P2Y 14 -R mRNA is highly abundant in circulating neutrophils (37) , and UDP-glucose promotes ERK1/2 phosphorylation in these cells (43) . Involvement of P2Y 14 -R activation in neutrophil function has, nonetheless, remained poorly defined. In the present study, we demonstrate that addition of UDPglucose to human neutrophils results in rapid and robust activation of RhoA, and this response occurs with concentration dependence consistent with a P2Y 14 -R-mediated response. UDP-glucose-evoked Rho activation was accompanied by changes in cell shape (with the formation of ruffle-like structures in one cellular pole), cytoskeleton rearrangements, and enhanced neutrophil chemotaxis. Furthermore, using the HL60 human promyelocytic leukemia cells, we demonstrate that UDP-glucose-evoked responses occurred in a P2Y 14 -R-dependent manner. That is, UDP-glucose had no effect on HL60 cells lacking P2Y 14 -R mRNA expression, but strong UDP-glucoseevoked RhoA activity was observed after either inducing endogenous expression of the receptor via DMSO differentiation (dHL60 cells) or stably expressing the P2Y 14 -R via retroviral infection (P2Y 14 -HL60 cells).
A caution was introduced by Brautigam et al. (3) for studies of inflammatory and other effects potentially regulated by the P2Y 14 -R. That is, although commercial sources of UDP-glucose induced inflammatory effects in N9 microglia, this action was only observed with high micromolar (Ͼ75 M) concentrations of bacterially derived but not synthetic UDP-glucose; other nucleotide sugars such as UDP-galactose also had no effect (3) . The conclusion that actions of UDP-sugars on neutrophils reflected activation of P2Y 14 -R is firmly supported by the following observations: 1) HPLC analysis of UDPglucose indicated no detectable contamination with ATP or any other nucleotide signaling molecule; moreover, the nucleotide di-and tri-phosphohydrolase apyrase (1 U/ml) was included in the PMN suspension medium during the Rho assay to minimize neutrophil activation by ATP/UTP potentially released during PMN isolation (28); 2) both RhoA activation and cell migration in the presence of UDP-glucose were virtually eliminated by preincubation of UDP-glucose with nucleotide pyrophosphatase, which hydrolyzes UDP-sugars (31), but not by apyrase; 3) neutrophil activation occurred with concentrations of UDP-glucose consistent with P2Y 14 -R activation; and 4) UDPglucose, UDP-galactose, and UDP-N-acetylglucosamine promoted RhoA activation in dHL60 cells, which natively express P2Y 14 -R (16) , and in undifferentiated HL60 cells expressing recombinant P2Y 14 -R, but not in wild-type undifferentiated HL60 cells, which do not express P2Y 14 -R (16) .
Extensive literature associates P2Y 14 -R-promoted responses with activation of heterotrimeric G proteins of the G i subfamily (reviewed in Ref. 21) . Our results illustrating that pertussis toxin abolishes UDP-glucose-promoted RhoA activation in dHL60 and P2Y 14 -HL60 cells are consistent with this notion. We also showed that RhoA activation was inhibited by a selective inhibitor of PI-3-kinase, a downstream effector of G i (20, 49) . Based on these results, we propose that the P2Y 14 -R promotes activation of G i , resulting in G␤␥-evoked PI-3-kinase-mediated formation of phosphatidylinositol (3, 4, 5) trisphosphate, recruitment of a Rho G protein exchange factor to the plasma membrane, and facilitation of RhoGTP formation. Such a signaling pathway was previously illustrated with formyl peptide-stimulated monocytes (7) .
The present study provides evidence for a functional role of the neutrophil P2Y 14 -R, i.e., modulation of neutrophil shape change and motility. Furthermore, our observation that Rho kinase inhibitors markedly reduced neutrophil motility are in line with studies indicating that activation of RhoA/Rho kinase results in myosin activation, rear contraction, and development of cell polarity in migrating neutrophils (32, 40, 54, 55) . RhoA activation in neutrophils and dHL60 cells was robust after 1 min of UDP-glucose addition, and time course measurements in dHL60 cells indicated that this response persisted for up to 15 min and faded after 30 min. These observations are consistent with studies indicating that rapid, transient increase of RhoA activity in the first minutes after agonist treatment is necessary for migration of leukocytes (1, 55) and other cells (19, 50, 56) . They are also in agreement with the notion that RhoA activity is subjected to negative feedback by Rho-GTPase activating proteins (GAPs) and Rho GDP dissociation inhibitor (RhoGDI) (13, 48) . Whether additional signaling pathways associated with chemoattractant-evoked responses, e.g., Rac1, Rac2, and Cdc42 (34, 39, 40) , contribute to P2Y 14 -R-regulated neutrophil shape change and locomotion remain to be investigated.
ATP release from stimulated phagocytes provides autocrine regulation of directional migration (12) . For example, formyl peptides, interleukin 8, C5a complement, and leukotriene LTB4 promote neutrophil migration, which was accompanied by ATP release and inhibited by apyrase or P2Y 2 -R antagonists (8, 9) . In line with these reports, UDP-glucose evoked chemotaxis of neutrophils and dHL60 cells was partially reduced when apyrase was included in the upper level of the Boyden chamber ( Figs. 3B and 7B) . Thus, endogenous ATP likely contributed, at least in part, to UDP-glucose-evoked neutrophil chemotaxis.
Recent data from our group demonstrated that, in addition to UDP-sugars, the P2Y 14 -R is activated by UDP (53) . Since UDP is also a potent agonist at the P2Y 6 -R and P2Y 6 -R transcripts are endogenously expressed in neutrophils and HL60 cells (22) , the relative contribution of P2Y 14 -R to UDPpromoted signaling in these cells could not be readily assessed. The effect of UDP on P2Y 14 -R-mediated responses was not investigated in the present study.
Our findings differ from those previously published by Arase et al. (2) . These authors reported that 1 M UDPglucose had no direct effect on PMN chemotaxis, assessed via the classic transwell filter staining method (2) . Addition of 1 M UDP-glucose to the lower compartment of the chemotaxis chamber in our studies resulted in a relatively minor response, as compared with the response observed with 10 M UDP-glucose ( Fig. 3C ). However, measurement of UDP-[ 3 H]glucose diffusion through the filter membrane indicated that the concentration of UDP-glucose in the upper compartment of the chamber at the time of quantification of chemotaxis (1 h) was only 20% of the nominal concentration of agonist added to the lower chamber (Fig. 3C, inset) . We suggest that the sensitive quantification provided by the automated, fluorescence-based chemotaxis assay used here as well as the difficulty of accurate estimation of the effective agonist concentration in situ account for the apparent discrepancy between the two studies.
The concept that the P2Y 14 -R plays (patho)physiologically relevant roles is supported by studies demonstrating that UDPglucose, UDP-galactose, and UDP-N-acetylglucosamine are released from cells in a regulated manner (14, 23, 24, 26, 31, 41, 46) . Moreover, unlike other proinflammatory molecules that require activation of biosynthetic pathways before their release from cells, UDP-glucose is highly abundant both in the cytosol and secretory pathway of most cells, and it is poised for rapid release together with other nucleotides and nucleotidesugars from activated and/or damaged cells (30) . Importantly, in contrast to short-lived ATP/UTP find-me signals released during sterile inflammatory processes (30, 35, 36) , extracellular UDP-glucose is highly stable (31) and is not degraded by neutrophil ecto-nucleotidases ( Fig. 1) . Thus, UDP-glucose likely is a novel, important local contributor to sterile neutrophilic inflammation.
Our present findings are particularly relevant to human airway pathophysiology. That is, we recently illustrated that Ca 2ϩ -regulated exocytosis of specialized mucin granules from goblet cell-reach airway epithelia is accompanied by robust release of UDP-glucose (23, 41) . We also have shown that lung secretions from cystic fibrosis patients displaying neutrophil lung inflammation contain elevated levels of UDP-glucose and UDP-N-acetylglucosamine, i.e., capable of promoting P2Y 14 -R activation (46) . An indirect proinflammatory action of UDPglucose in the lung has been previously suggested by studies illustrating that UDP-glucose promoted secretion of IL-8 from primary human alveolar type II cell-enriched cultures (38) . Our present study suggests an additional, direct role of the neutrophil P2Y 14 -R as a contributor to lung inflammation in chronic lung diseases.
In summary, we demonstrate that UDP-glucose is a highly stable proinflammatory mediator that promotes P2Y 14 -R-regulated RhoA activation, cytoskeleton rearrangements, and chemotaxis in human neutrophils.
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